Open Access. Powered by Scholars. Published by Universities.®

Operations Research, Systems Engineering and Industrial Engineering Commons

Open Access. Powered by Scholars. Published by Universities.®

Series

2011

VX

Articles 1 - 2 of 2

Full-Text Articles in Operations Research, Systems Engineering and Industrial Engineering

Prophylaxis With Human Serum Butyrylcholinesterase Protects Guinea Pigs Exposed To Multiple Lethal Doses Of Soman Or Vx, Ashima Saxena, Wei Sun, James M. Fedorko, Irwin Koplovitz, Bhupendra P. Doctor Jan 2011

Prophylaxis With Human Serum Butyrylcholinesterase Protects Guinea Pigs Exposed To Multiple Lethal Doses Of Soman Or Vx, Ashima Saxena, Wei Sun, James M. Fedorko, Irwin Koplovitz, Bhupendra P. Doctor

US Army Research

Human serum butyrylcholinesterase (Hu BChE) is currently under advanced development as a bioscavenger for the prophylaxis of organophosphorus (OP) nerve agent toxicity in humans. It is estimated that a dose of 200 mg will be required to protect a human against 2 × LD50 of soman. To provide data for initiating an investigational new drug application for the use of this enzyme as a bioscavenger in humans, we purified enzyme from Cohn fraction IV-4 paste and initiated safety and efficacy evaluations in mice, guinea pigs, and non-human primates. In mice, we demonstrated that a single dose of enzyme that is ...


Determination Of Threshold Adverse Effect Doses Of Percutaneous Vx Exposure In African Green Monkeys, Raymond F. Genovese, Bernard J. Benton, John L. Oubre, Christopher E. Byers, E. Michael Jakubowski, Robert J. Mioduszewski, Timothy J. Settle, Thomas J. Steinbach Jan 2011

Determination Of Threshold Adverse Effect Doses Of Percutaneous Vx Exposure In African Green Monkeys, Raymond F. Genovese, Bernard J. Benton, John L. Oubre, Christopher E. Byers, E. Michael Jakubowski, Robert J. Mioduszewski, Timothy J. Settle, Thomas J. Steinbach

US Army Research

Percutaneous exposure to the chemical warfare nerve agent VX was evaluated in African green monkeys (n = 9). Doses of VX (7.5–100 μg/kg) were applied to the skin for 60 min and residual agent was quantified (before decontamination) to estimate the absorbed dose. Monkeys were evaluated for the presence or absence of clinical signs of toxicity and blood was sampled periodically (30 min–12 weeks) following exposure to measure the degree of circulating acetylcholinesterase (AChE) inhibition. Monkeys were also evaluated for behavioral changes fromVXexposure using a serial probe recognition (SPR) task. The lowest observable adverse effect level (LOAEL ...